

Please type a plus sign (+) inside this box → ☒

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


Application Number	09/412,297
Filing Date	October 5, 1999
First Named Inventor	TING, Kang
Group Art Unit	1645
Examiner Name	V. Ford
Attorney Docket Number	407T-962900US

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input checked="" type="checkbox"/> Declaration of Inventor under 37 CFR 1.131	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input checked="" type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input checked="" type="checkbox"/> Diskette containing Sequence Listing	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input checked="" type="checkbox"/> Paper copy of the Sequence Listing	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input checked="" type="checkbox"/> Copy of "Notice to Comply with Req. for Patent App. Containing Nucleotide Seq..."	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	receipt acknowledgment postcard; PTO form 1449; Cited References; Appendix A (marked up copy of specification and claims) and Appendix B (courtesy copy of pending claims).
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Susan T. Hubl, Reg. No. 47,668, Quine Intellectual Property Law Group P.C.
Signature	
Date	March 22, 2002

CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: March 22, 2002

Typed or printed name	Amelia Groth		
Signature		Date	March 22, 2002

Thereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on MARCH 22, 2002.

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By



AMELIA GROTH

Attorney Docket No.: 407T-962900US

Client Ref. No.: 1999-560-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

TING, Kang

Application No.: **09/412,297**

Filed: October 5, 1999

For: NELL-1 ENHANCED BONE
MINERALIZATION

Examiner: Ford, V.

Art Unit: 1645

RESPONSE TO OFFICE ACTION
PURSUANT TO 37 C.F.R § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated **September 24, 2001**, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

The following documents are enclosed herewith:

- 1) A transmittal sheet;
- 2) A petition to extend the period of response for 3 months (+ one copy);
- 3) A Declaration of Kang Ting under 37 CFR 1.131;
- 4) An initial CRF copy of the "Sequence Listing;"
- 5) A substitute paper copy of the "Sequence Listing;"
- 6) A copy of the "Notice to Comply with Requirements For Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;"
- 7) A version to show changes made to the specification and claims (Appendix A);
- 8) A courtesy copy of the pending claims (Appendix B);
- 9) A set of new, corrected formal drawings;